Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kavitha Beedupalli

Hematology & Oncology Shreveport, LA Medical Doctor

NPI 1568694321 CMS profile 1375263

1501 Kings Hwy, Shreveport, LA 71103

Open in the dashboard

General payments

$15,398

261 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kavitha Beedupalli of Shreveport, LA is reported in the CMS Open Payments database as having received $15,398 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,970 95
2024 General $1,388 63
2023 General $1,142 51
2022 General $489 28
2021 General $56 4
2020 General $88 6
2019 General $265 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kavitha Beedupalli
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Kavitha Beedupalli were reported at $11,970. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Kavitha Beedupalli Hematology & Oncology median Middle half National median
2019 $265 $529 $121–$2,516 $163
2020 $88 $339 $82–$2,213 $114
2021 $56 $263 $49–$1,965 $132
2022 $489 $416 $103–$2,395 $149
2023 $1,142 $542 $125–$2,646 $160
2024 $1,388 $692 $141–$3,008 $164
2025 $11,970 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $8,998 14 payments
  2. Intuitive Surgical, Inc. $1,280 4 payments
  3. Daiichi Sankyo Inc. $649 32 payments
  4. AstraZeneca Pharmaceuticals LP $489 25 payments
  5. Merck Sharp & Dohme Corporation $452 21 payments
  6. Gilead Sciences, Inc. $342 14 payments
  7. E.R. Squibb & Sons, L.L.C. $276 15 payments
  8. Novartis Pharmaceuticals Corporation $252 13 payments
  9. AbbVie, Inc. $245 12 payments
  10. Janssen Biotech, Inc. $193 11 payments
  11. Other $2,222 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,025 1 payment
  2. Food and Beverage $5,498 248 payments
  3. Travel and Lodging $1,771 5 payments
  4. Education $104 7 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,280 4 payments
  2. ENHERTU $415 18 payments
  3. KEYTRUDA $387 18 payments
  4. IMFINZI $367 18 payments
  5. TECENTRIQ $319 10 payments
  6. Trodelvy $253 8 payments
  7. OPDIVO $247 13 payments
  8. EPKINLY $247 12 payments
  9. Fabhalta $199 10 payments
  10. Stivarga $184 7 payments
  11. Other $3,532 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$44,140

Medicare's payments for the services billed

Medicare patients

137

Average age 70

Services billed

544

56 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Cancer 53%
Arthritis 34%
COPD 33%
Diabetes 30%
Ischemic heart disease 26%
Chronic kidney disease 26%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $208
$208 — —
Trodelvy
  • Gilead Sciences, Inc. $125
$125 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $115
$115 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $96
$96 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record